Conference item icon

Conference item

Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma.

Abstract:

PURPOSE: To evaluate low-dose extended duration interferon alfa-2a as adjuvant therapy in patients with thick (> or = 4 mm) primary cutaneous melanoma and/or locoregional metastases. PATIENTS AND METHODS: In this randomized controlled trial involving 674 patients, the effect of interferon alfa-2a (3 megaunits three times per week for 2 years or until recurrence) on overall survival (OS) and recurrence-free survival (RFS) was compared with that of no further treatment in radically resected ...

Expand abstract
Publication status:
Published

Actions


Access Document


Publisher copy:
10.1200/jco.2004.03.185

Authors


Host title:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Volume:
22
Issue:
1
Pages:
53-61
Publication date:
2004-01-01
Event location:
United States
DOI:
EISSN:
1527-7755
ISSN:
0732-183X
Keywords:
Pubs id:
pubs:331344
UUID:
uuid:095d4fb6-378b-44bb-8a54-c97678b9499f
Local pid:
pubs:331344
Source identifiers:
331344
Deposit date:
2012-12-19

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP